Is the Cost of Wegovy Going Down in the UK?

Step 1: Understand why UK private Wegovy prices have stayed high

The short answer is supply and demand. Wegovy has been on allocation in the UK for much of the past two years, with wholesaler supply tightly controlled by Novo Nordisk. When a medicine is hard to source reliably, providers cannot compete on price in the usual way. The private market has broadly settled into a range of roughly £149 to £375 per month depending on dose and provider, figures that have been widely reported and are consistent with the trajectory since 2023.

There is one meaningful development on the horizon. The full picture of Wegovy's licensed doses in the UK has expanded: the MHRA approved a dedicated single-dose 7.2mg pen in April 2026, which may introduce new pricing variables as higher-strength supply stabilises. If you are wondering whether Wegovy prices are going up, the honest picture is that the private market still reflects real costs around clinical oversight, genuine supply-chain sourcing and prescriber time. For now, the current state of Wegovy pricing reflects a private market where those costs all carry real weight.

NICE's recommendation for Wegovy (TA875) sets criteria for NHS access through specialist weight management services, but NHS waiting lists are long. Private treatment fills a genuine gap, and the price reflects that.

Step 2: Look at what a headline price actually covers

This is where comparison gets complicated. A monthly price quoted on a provider's landing page may or may not include your initial consultation, the cost of the prescription, delivery, and any ongoing clinical support if you have questions between doses. Some services charge separately for each of those. A figure that looks lower sometimes becomes comparable once those extras are added.

A question our prescribers hear regularly is whether a cheaper-looking service is cutting corners on the clinical side. The honest answer is: sometimes. Services that quote a price without making the prescriber review process clear are worth scrutinising. Finding a low Wegovy price is one thing; knowing what that price actually buys you is another. If you are curious about whether the price of Wegovy has gone down, it is worth checking not just the headline figure but exactly what clinical oversight it includes. At the very least, check that any pharmacy you use is listed on the GPhC register, it takes thirty seconds and it matters.

The MHRA has issued clear warnings about fake weight-loss pens sold through social media and unverified websites. Prices that look dramatically below the market range are a red flag, not a bargain.

Step 3: Factor in what a single transparent price means in practice

At nume, a single price covers your consultation, your prescription, your treatment and free next-working-day tracked delivery, no extras, no subscription. A real clinician reads your answers; your order, placed before midday on a working day, is dispatched the same day once approved. Some people place their order on a Monday morning, others on payday at the end of the month. The process is the same either way.

We are not the cheapest option in the private market. That is a deliberate choice. Investing in GPhC-registered prescribers who review every consultation personally, in a licensed UK supply chain, and in genuine seven-day aftercare costs money that a stripped-back service can avoid. Whether that trade-off is right for you is something only you can weigh. You can read more about how nume works or review common questions about the service before you start.

It is also worth noting that Wegovy's NICE-recommended pathway under TA875 requires a specialist weight management setting and a maximum treatment duration of two years on the NHS, private prescribing follows the licensed criteria, without those NHS-specific constraints.

Step 4: Ask the right question about cost

Price is an understandable starting point when you are budgeting for ongoing treatment. But for a prescription-only medicine, cost alone is the wrong filter. The questions worth asking are whether the prescriber is qualified, whether the supply chain is legitimate, and whether there is clinical support if something feels off after you start.

Semaglutide (Wegovy's active ingredient) is also the molecule in Ozempic, which is licensed for type 2 diabetes, not weight management. If you come across pricing for Ozempic positioned as a weight-loss medicine, that is worth understanding clearly before proceeding. The NHS semaglutide medicines page sets out the difference plainly.

If you want to explore whether Wegovy is clinically suitable for you, the most straightforward next step is a free consultation. There is no obligation, and a prescriber will tell you honestly whether treatment is appropriate. You can find out about all available weight-loss treatments at nume and what the consultation involves before you commit to anything.